Full-Time
Director Worldwide Autoimmune Cell Therapy Medical Affairs
Posted on 6/12/2026
Bristol Myers Squibb
10,001+ employees
Global biopharma researching, developing, delivering medicines
No salary listed
Company Historically Provides H1B Sponsorship
Princeton, NJ, USA
Hybrid
Three days on-site per week required.
PharmD, PhD, MD
 Biology & Biotech (1) |
|---|
Get referred to Bristol Myers Squibb
See people who can refer or advise you
- Advanced, scientific or medical degree (e.g. Doctor of Medicine, Doctor of Osteopathy, Nurse Practitioner, Physician Assistant, PharmD, PhD)
- Minimum 5+ years of experience in the pharma/biopharma industry or clinical practice
- Advanced understanding of drug development, pharmaceutical and healthcare industries
- Strong leadership experience in a matrix environment with multi-functional project teams and managing external agencies
- Strong interpersonal communication skills to work with external physicians/scientists and in-house teams
- Ability to navigate complex topics in a matrix environment with grace and confidence
- Strong listening, problem solving, and prioritization skills
- Excellent planning and organization skills including the ability to work under pressure and maintain scientific excellence within timelines
- Excellent written and oral communication skills, including strong oral presentation skills
- Ability to maintain the highest degree of confidentiality and integrity; representing the company’s high ethics and professionalism standards
- Headquarters-based position with global travel expected up to 25%
- Lead development and execution of the worldwide autoimmune cell therapy medical affairs strategy for early assets, including annual and quarterly strategic planning, cross-functional alignment, and governance support to advance key program milestones
- Serve as a strategic cross-functional medical affairs leader, partnering with Clinical Development, Commercial, Market Access, HEOR, and other stakeholders to drive coordinated execution, decision making, and operational excellence across priority initiatives
- Lead planning and execution of external scientific and clinical engagement activities, including advisory boards, scientific forums, and other medical affairs programs, ensuring compliant scientific exchange and translation of expert insights into actionable medical strategies, inform scientific and development strategy, lifecycle planning, and future indication readiness
- Support development of external medical education and capability-building initiatives that strengthen understanding of the potential of cell therapy in management of autoimmune diseases across relevant specialties and help address the evolving clinical practice needs
- Partner with internal and external stakeholders to shape and execute evidence generation plans, including investigator-sponsored research, collaborative studies
- Incorporate the patient perspective into medical affairs planning by collaborating with appropriate partners on patient insights, advocacy engagement, and unbranded educational initiatives that support awareness, access, and the patient care journey
Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1887
Get referred to Bristol Myers Squibb
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 5% to $12.97 billion; guidance lifted to $49-$50 billion.
- Eliquis sales jumped 21% in Q2 2026, offsetting legacy portfolio declines.
- Houston's 500 jobs and $2.3 billion investment strengthen U.S. supply resilience.
What critics are saying
- Cytokinetics sued BMS on August 13, 2026 over the '697 patent.
- Eliquis and Opdivo face exclusivity erosion; both drove half of 2025 revenue.
- NJ layoffs and $2 billion cuts signal pipeline weakness, not just efficiency.
What makes Bristol Myers Squibb unique
- BMS owns Eliquis and Opdivo, still core franchises despite patent cliffs.
- Houston campus adds flexible U.S. biologics, ADC, and small-molecule manufacturing by 2030.
- Nvidia and Schrödinger collaborations deepen BMS's AI-driven drug discovery stack.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Hybrid Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 7%Cytokinetics sues Bristol Myers to void a new patent. Cytokinetics has asked a court to strike down a newly granted Bristol Myers Squibb patent, moving a hard-fought commercial fight between two cardiac drug developers into the courtroom. Cytokinetics Inc (NASDAQ: CYTK) filed suit against Bristol-Myers Squibb Co (NYSE: BMY) on Wednesday seeking to invalidate a recently granted Bristol patent, turning a commercial rivalry between the two heart-drug developers into litigation; Cytokinetics traded at $74.18, up 0.99%, while Bristol was at $64.29, down 0.56%, as of 18:56 GMT on Aug. 14, 2026. Cytokinetics Inc (NASDAQ: CYTK) has taken its fight with Bristol-Myers Squibb Co (NYSE: BMY) out of the sales channel and into a courtroom. The company filed a lawsuit on Wednesday seeking to invalidate a patent recently granted to Bristol, according to Endpoints News, which described the two drugmakers as fierce market rivals now facing each other as litigants as well. The move is unusual in its direction. Patent fights in branded pharma are typically brought by the patent holder against a would-be entrant. Here the challenge runs the other way: the smaller company is asking a court to strike down protection the larger one has just secured, rather than waiting to be accused of infringing it. That is the posture a company adopts when it believes a competitor's newly issued claims could be read broadly enough to reach across the aisle. A commercial rivalry that had nowhere else to go. Cytokinetics and Bristol have spent years on opposite sides of the same therapeutic problem: treating patients whose heart muscle contracts too forcefully. Bristol got there first commercially through its acquisition of MyoKardia and the cardiac myosin inhibitor franchise that came with it. Cytokinetics has built its identity around its own next-generation candidate in the same mechanism class. Two companies chasing the same prescriber base with drugs that work the same way is a recipe for overlapping intellectual property, and eventually for someone testing the boundaries in court. For Cytokinetics, the stakes are structural. It is a company whose valuation rests heavily on a single cardiovascular program and the freedom to commercialize it without paying tolls to a competitor. A patent that shadows that launch is not a nuisance; it is a claim on future margin. Filing to invalidate it early, before any infringement allegation forces the company onto the back foot, keeps the initiative on Cytokinetics' side of the table and puts a clock on the dispute. For Bristol, the calculus is different. The company is large enough that a single patent challenge on one cardiology asset does not move the consolidated picture much. But it is also a company managing a well-documented loss-of-exclusivity cycle across older products, which makes newer, growing franchises disproportionately important to the forward story. Defending the durability of protection around a growth product matters more than the immediate dollars in dispute. Where the two stocks stood as the filing landed. Markets treated the news as a governance-and-timeline item rather than a shock. As of the last trade at 18:56 GMT on Friday, Aug. 14, 2026, Cytokinetics changed hands at $74.18, up 0.99% on the day from a prior close of $73.45, having traded between $72.12 and $74.27. Bristol was at $64.29, down 0.56% from a prior close of $64.65, in a $63.35 to $64.33 range. The backdrop was mildly negative. The S&P 500, via SPY, was at $776.29, off 0.20%; the Nasdaq 100 proxy QQQ was at $729.84, down 0.30%; and the Dow tracker DIA sat at $537.48, lower by 0.08%. Against that, Cytokinetics' gain reads as modest relative outperformance and Bristol's decline as roughly in line with a soft tape. Neither move suggests investors have repriced the outcome of the case in either direction - which is what you would expect at the filing stage, when there is a complaint on a docket and nothing else. What actually gets decided, and how slowly. Patent invalidation is a long game. A declaratory action of this kind typically has to clear procedural questions first - whether the plaintiff has standing to sue over a patent it has not been accused of infringing, and whether the dispute is ripe. Only then does a court reach the substance: whether the claims as granted are novel and non-obvious in light of what was already known. Appeals follow. Nothing about the trajectory of either company's revenue changes in the next quarter because of a complaint filed on a Wednesday. Only then does a court reach the substance: whether the claims as granted are novel and non-obvious in light of what was already known. What can change sooner is behavior. Litigation of this type often runs in parallel with, or ends in, a negotiated outcome - a license, a royalty, a covenant not to sue, a narrowing of claims. Companies file to create leverage as often as to win a judgment. The existence of the suit tells you the parties could not reach terms privately; the eventual resolution will tell you which side had the stronger read on the claims. Signals worth tracking from here. * Bristol's response. A counterclaim for infringement would sharpen the dispute considerably and signal confidence in the patent's breadth. A motion to dismiss on standing would suggest a preference to keep the claims untested. * Parallel administrative challenges. Invalidity arguments are frequently pressed at the patent office as well as in district court. A second front would show Cytokinetics is committed to the fight rather than posturing. * Language in filings and calls. Risk-factor updates and any discussion of the litigation in quarterly disclosures will indicate how material each company considers the exposure. * Commercial share. The court case is a sideshow to the real contest - which drug prescribers reach for. Prescription trends will drive both stocks far more over the next year than any docket entry. For investors, the practical framing is that this is a risk-boundary story, not an earnings story. Cytokinetics is trying to remove an obstacle before it becomes expensive; Bristol is defending an asset it paid to acquire. Both objectives are rational, which is precisely why the matter ended up in front of a judge. Key facts. * Cytokinetics (NASDAQ: CYTK): $74.18, +0.99%, as of 18:56 GMT Aug. 14, 2026 * Bristol-Myers Squibb (NYSE: BMY): $64.29, -0.56%, as of 18:56 GMT Aug. 14, 2026 * Action filed: Lawsuit brought Wednesday seeking to invalidate a recently granted Bristol patent * Market backdrop: S&P 500 proxy SPY $776.29 (-0.20%); Nasdaq 100 proxy QQQ $729.84 (-0.30%) Frequently asked questions. What did Cytokinetics actually file? Cytokinetics filed a lawsuit against Bristol Myers Squibb on Wednesday asking a court to invalidate a patent that had recently been granted to Bristol. Rather than defending itself against an infringement claim, Cytokinetics is affirmatively challenging the validity of the competitor's newly issued patent claims before any dispute over infringement is brought against it. Why would a company sue to cancel a rival's patent? Because a broadly worded patent held by a competitor can create royalty obligations, injunction risk or licensing leverage over a product a company plans to sell. Challenging validity early removes that overhang on the challenger's own timetable instead of leaving it to the patent holder to choose when and where to press an infringement claim. How did the two stocks react? Modestly and in opposite directions. As of the last trade at 18:56 GMT on Aug. 14, 2026, Cytokinetics was at $74.18, up 0.99% from a $73.45 prior close, while Bristol-Myers Squibb was at $64.29, down 0.56% from $64.65. Broad indices were slightly lower the same session, so neither move implies a decisive market verdict. How long could the litigation take? Patent invalidity disputes generally run for years. A court must first address procedural questions such as standing and ripeness, then reach the merits of whether the claims are novel and non-obvious, with appeals possible afterward. Many such cases settle before final judgment through licensing terms or a narrowing of the disputed claims. Does this change either company's financial outlook now? No. A complaint being docketed does not alter reported revenue, costs or guidance in the near term. The financial consequence, if any, arrives later through a judgment, a license, a royalty arrangement or legal expense. In the meantime prescription trends and commercial execution matter far more to both stocks. What should investors watch next in the case? Bristol's response is the key signal: a counterclaim alleging infringement would escalate matters, while a motion to dismiss on standing grounds would suggest an effort to avoid testing the patent. Also worth tracking are any parallel challenges at the patent office and how each company characterizes the exposure in its disclosures.
A US federal appeals court has revived a $6.7 billion lawsuit against Bristol Myers Squibb brought by UMB Bank on behalf of former Celgene shareholders. The 2nd US Circuit Court of Appeals unanimously reinstated the case, which alleges Bristol Myers deliberately delayed FDA approval for three drugs to avoid paying shareholders. The dispute stems from Bristol Myers' $80.3 billion acquisition of Celgene in 2019. Celgene shareholders with contingent value rights were entitled to $9 per share if Bristol Myers secured timely FDA approvals for three drugs, including cancer therapy Breyanzi. Breyanzi received approval five weeks past the contractual deadline in February 2021. The appeals court ruled that UMB Bank had proper standing to sue, reversing a lower court's September 2024 dismissal. Breyanzi generated $484 million in revenue for Bristol Myers in its most recent quarter.
AstraZeneca ends Bristol Myers Squibb deal. Wed, August 12, 2026 at 6:22 PM GMT-7 · Consumer · Compiled by Adalytica Engine v1.12 AstraZeneca has terminated its deal with Bristol Myers Squibb, ending a collaboration that underscored how quickly pharma alliances can be reshaped by rising U.S. investment and a renewed race for oncology assets. The cancellation, disclosed in an Aug. 3 filing, matters because partnerships in cancer drug development are not just research arrangements: they can determine how fast a therapy reaches patients, how costs are shared and how much future revenue each company can capture. In a sector where pricing power and pipeline quality drive valuation, the unwinding of a major tie-up forces investors to reassess both companies' strategic flexibility and the economics of their oncology portfolios. Sentiment Indicatorsi Proprietary · adalytica.com · August 13, 2026 Healthcare Severely Stressed AstraZeneca's shares were trading at 158.5 on Aug. 12, down from 193.12 on July 7, while Bristol Myers closed at 63.70 after recovering from a June trough of 54.95. The moves point to a market that is still sorting through the implications of the breakup and the broader re-rating of large drugmakers exposed to oncology and U.S. expansion. For AstraZeneca, the decision fits a larger pattern of pharmaceutical groups concentrating capital in the U.S., where demand, regulatory scale and innovation density remain unmatched. The company has been leaning on oncology as its main growth engine, and a cleaner strategic structure may give it more control over development and commercialization decisions. But it also raises the risk that the company must shoulder more of the cost and execution burden itself. For Bristol Myers, the end of the deal removes a potential source of pipeline support at a time when investors are already focused on whether the company can sustain growth as older drugs mature. The stock has been more resilient than AstraZeneca's over the latest stretch, helped by a stronger technical profile and a sharp rebound from June lows, but the loss of a collaboration with one of the sector's strongest oncology franchises may weigh on long-term sentiment. The broader backdrop is still favorable for companies with deep cancer pipelines. U.S. spending on pharma investment is rising, Chinese biotech competition is intensifying and regulators are tightening quality expectations, pushing global drugmakers to seek scale, speed and more defensible assets. In that environment, cancelled alliances can be read two ways: as a sign that companies are becoming more disciplined about capital allocation, or as evidence that the industry's partnership model is becoming less stable as the fight for returns gets tougher. For investors, the key question is whether AstraZeneca's move strengthens its control over future upside or simply shifts more risk onto its balance sheet. The answer will depend on whether it can turn its oncology pipeline into durable revenue without the support of a major partner, and whether Bristol Myers can replace lost strategic optionality with its own dealmaking or execution gains. | Entity | Gains | Losses | | AstraZeneca | | Strategic control | | Shared development cost | | Bristol Myers Squibb | | Capital flexibility | | Pipeline optionality | | Oncology rivals | | Dealmaking leverage | | Partnership stability | | Investors | | Clearer capital plans | | Near-term uncertainty | Long AstraZeneca / Short Bristol Myers Squibb AZN keeps more oncology upside Entry 158.50 Target 170.00 Stop 151.00 R:R 1: 1.53 Trade Idea Turn this analysis into a trade. Unlock the complete setup.
Lawsuit against Bristol Myers over delayed cancer drug is revived. By Thomson Reuters Aug 13, 2026 | 11:47 AM By Jonathan Stempel NEW YORK, Aug 13 (Reuters) - A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi. In a 3-0 decision on Thursday, the 2nd U.S. Circuit Court of Appeals in Manhattan said UMB Bank was entitled to represent the Celgene shareholders as a trustee despite an error in how it was appointed. Bristol Myers and its lawyers did not immediately respond to requests for comment. UMB and its lawyers did not immediately respond to similar requests. Thursday's decision revived a lawsuit that U.S. District Judge Jesse Furman in Manhattan dismissed in September 2024. It was not immediately clear how the decision affected UMB's similar lawsuit raising several new claims against Bristol Myers, and which Furman let proceed last December. BRISTOL MYERS ACCUSED OF BEING TOO SLOW The case arose from Bristol Myers' purchase of Celgene for $80.3 billion in 2019. Celgene shareholders who held "contingent value rights" (CVR) were entitled to an extra $9 per share in cash if Bristol Myers won timely U.S. Food and Drug Administration approvals for Liso-cel, which is sold as Breyanzi, and the drugs Ozanimod and Ide-cel. Some CVR holders grew concerned that Bristol Myers would miss the deadlines to avert a big payout, and hired UMB to replace an earlier trustee. UMB ultimately accused the drugmaker of failing to use "diligent efforts" to win approvals, and wrongly delisting the CVRs from the New York Stock Exchange before holders could enforce their rights. Bristol Myers won FDA approval for Breyanzi to treat non-Hodgkin lymphoma on February 5, 2021, five weeks after the relevant deadline. In a December court filing, the Princeton, New Jersey-based company denied UMB's claims that it slow-rolled the approval process and tried to undermine the CVR holders' rights. DRUGMAKER 'NOT CONFUSED' The appeals court said UMB had standing to sue because Bristol Myers, the prior trustee and a majority of the CVRs' "beneficial owners" approved UMB's appointment, though the investors were not "registered" owners as defined in the CVR agreement. "Bristol Myers was not confused about the status of the investors who purported to appoint UMB," Circuit Judge Beth Robinson wrote. In his December ruling, Furman allowed Kansas City, Missouri-based UMB to pursue some claims against Bristol Myers, including breach of contract and failure to act in good faith. (Reporting by Jonathan Stempel in New York; Editing by Kirsten Donovan)
Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory. Aug 11, 2026 | 9:00 am New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site. The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park. BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030. "We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release. The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration." "Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region's ability to support a world-class, digitally advanced supply operation," Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. "This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands." Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program. "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare," Abbott said in a news release. "This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers." "Bristol Myers Squibb's announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing," added Greater Houston Partnership President and CEO Steve Kean. Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here. This story was first published on its sister site InnovationMap. all about that base Houston hero JJ Watt sparks new investment in Texas energy startup. Aug 7, 2026 | 10:45 am Houston Texans legend J.J. Watt is an investor in and customer of Austin-based energy startup Base Power. Courtesy of Base Power Since retiring from the NFL three years ago, Houston Texans legend J.J. Watt has been exploring a new field - investing. In 2023, the former defensive end and current CBS Sports football analyst bought a stake in English soccer team Burnley FC. A year later, he invested in the PopUp Bagels chain. This summer, Watt made what may be his highest-profile investment yet. He contributed to a $1 billion Series D round for Austin-based energy startup Base Power, which has an office in Houston. It's Watts' first investment in the energy sector. "I like companies that solve real problems, and Base is lowering power bills, protecting families, and building the whole thing themselves right here in Texas," Watt said in a company news release. "What impressed me wasn't just how fast they've grown," he adds. "It's that they've already saved Texans millions on their power bills and kept thousands of homes running when the lights went out. That's why I invested." Base Power is building a distributed network of residential batteries that's designed to strengthen the grid and lower electrical bills. The startup now powers more than 30,000 homes in Texas, including the Houston area, and recently expanded to Illinois. Base Power's $1 billion round lifted its valuation to $13 billion. Since being founded in 2023, the startup has raised more than $2.5 billion. "JJ is a legend in this state, and he earned that as much for how he shows up off the field as for what he did on it," says Zach Dell, co-founder and CEO of Base Power. "He spent a full day with us asking every hard question he could think of, and then he switched to Base himself. We're glad to have him partnering with us." Zach Dell is the only son of Austin billionaire Michael Dell, chairman and CEO of Round Rock-based Dell Technologies. Michael Dell grew up in Bellaire. This story was first published on its sister site EnergyCapitalHTX.